Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 13, 2008

View Archived Issues

Nucleoside reverse transcriptase inhibitor active in mouse AIDS model

Antiretroviral compound may have distinct mechanism of action

Reduction of CSF biomarkers with PBT-2 treatment in phase II study

MyD88 deficiency associated with rare pyogenic bacterial infections in children

Vertex offers Q2 overview

Cannabinoid receptor 1 identified as colorectal cancer target

Oxycyte in development as gel for surface wounds

Acrux and KV sign expanded agreement for Evamist and other products

Peregrine initiates patient screening and dosing in phase II trial of bavituximab

PhytoMedical acquires worldwide license rights to Dartmouth's novel anticancer compounds

Starpharma initiates clinical trial to measure level of antiviral activity retained by VivaGel

Sanofi-aventis exercises option for expanded access to ImmunoGen's TAP technology

FDA accepts Pain Therapeutics' NDA for Remoxy and grants priority review

SF-1019 approved in Malaysia

NCI initiates enrollment in phase II clinical trial of Reolysin

Shire: Q2 update

MedImmune initiates phase IIa clinical trial of Medarex's MEDI-545 in SLE

Canopus Biopharma reports positive results from mouse study of StatC in H5N1, H1N1 and H3N2

Cerus is granted CE mark for Intercept in treatment of previously frozen plasma

New agents for metabolic disorders described in recent patents

New analgesic agents revealed in recent patents

Recent patents describe novel agents for asthma, allergy, etc.

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...